Human Microbiome Health

Exploring New Frontiers in Human Microbiome Health

Sara Vidal Sara Vidal in our research lab.

Scientific research is increasingly understanding the unique impact complex and diverse glycans have on immunity and metabolic health.

With this emerging understanding, Gnubiotics has begun applying its innovative glycan technologies to design products which modulate the microbiome safely and effectively by selectively promoting the growth of essential commensal microbes, controlling pathogenic microbes and enhancing the production of metabolites essential for immune protection and regulating inflammatory responses.

Gnubiotics has begun its preclinical research with the goal of enhancing the efficacy of anti-cancer drugs such as ICI’s and act as an anti-inflammatory agent when treating chronic inflammatory diseases such as IBD.

Immuno-oncology

Although immunotherapies have revolutionized the treatment of some cancers, response rates remain suboptimal and differ between patients.

Our candidates aim to capture the therapeutic utility of directly manipulating the microbiome as an approach to control tumoral growth and enhance the efficacy of cancer immunotherapies such as PD-1/PD-L1 inhibitors. Our candidates promote a high microbiome diversity, now recognized as an essential asset in treatment response, and exploit the link between gut microbiota and immune physiology to affect tumor growth and treatment outcome.

Our candidates are currently being tested with the University of Zürich (Switzerland) in mice models of CRC and melanoma tumors.

medicines

Antimicrobial resistance

CRE, ESBL, VRE and MDR P. aeruginosa are all recognized as urgent and serious antibiotic resistance threats by the US Centers for Disease Control (CDC).

Through their ability to fortify the microbiome and selectively promote commensal bacteria over pathogens, our candidates aim to reduce colonization by these pathogenic bacteria and support the maintenance of the intestinal barrier, limiting subsequent systemic infection.

Our candidates are currently being tested in collaboration with NIAID to demonstrate safety and efficacy.

Inflammatory & metabolic diseases

Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the intestinal tract. Worldwide, over 2.5 million people of European ancestry are affected.

It becomes apparent that an imbalance of the intestinal flora leads to an activation of the immune system that can cause the disease. Our candidates aim to restore the microbiome to a state that supports the epithelial barrier and exerts immunoregulatory function.

Our candidates are currently being tested in collaboration with the University of Zürich (Switzerland) in mice models to demonstrate that they can act as anti-inflammatory agents.

Products & Pipeline Candidates

Our Pipeline:
Candidates & Indications
Discovery
Pre-clinical
Efficacy
Market
Collaborator
Human - Supportive Care
GCX/GBX

ℹ AMR infection


CRE, ESBL, VRE, MDR P. aeruginosa
GCX/GBX

ℹ Inflammatory & Metabolic


IBD
GCX/GBX

ℹ Immuno-oncology


Colorectal cancer
GCX/GBX

ℹ Immuno-oncology


Melanoma
×

PRODUCT CANDIDATE OVERVIEW

GCX and GBX are product candidates intended to be orally administered to modulate the microbiome, activate metabolites and exert selective antimicrobial as well as immunomodulatory effects in humans. GCX and GBX contains a mix of tens of MO biosimilars in the form of glycopeptides.

PROGRESS

GCX and GBX are being tested in collaboration with NIAID in a pre-clinical program to demonstrate safety and efficacy against multi-drug resistant bacteria in a set of IND-enabling studies.

UNMET NEED

CRE, ESBL, VRE and MDR P. aeruginosa are all recognized as urgent and serious antibiotic resistance threats by the US CDC. CRE, ESBL and VRE are major concerns for patients in healthcare facilities and the community with about 15’000 deaths in 2017 in US alone. MDR P. aeruginosa is particularly dangerous for patients with chronic lung diseases and resulted in about 3’000 deaths in 2017 in US. Colonization of the intestine by these bacteria often preceded systemic infection. Unfortunately, antibiotics often increases susceptibility to infections by disrupting the protective microbiome.

MODE OF ACTION

GCX and GBX fortify the microbiome by favouring the growth of commensal bacteria and helps restoring its diversity and activity, thus GCX and GBX aim to reduce colonization by pathogenic bacteria and support the maintenance of the intestinal barrier, limiting subsequent systemic infection.

×

PRODUCT CANDIDATE OVERVIEW

GCX and GBX are product candidates intended to be orally administered to modulate the microbiome, activate metabolites and exert selective antimicrobial as well as immunomodulatory effects in humans. GCX and GBX contains a mix of tens of MO biosimilars in the form of glycopeptides.

PROGRESS

GCX and GBX are being tested in collaboration with University of Zürich (Switzerland) in mice models to demonstrate that they can act as anti-inflammatory agents to treat chronic inflammatory diseases, such as inflammatory bowel disease (IBD).

UNMET NEED

Inflammatory bowel diseases (IBDs) are chronic, relapsing inflammatory disorders of the intestinal tract and potentially causing a life-long burden and reduction of quality of life for the patients. Worldwide, over 2.5 million people of European ancestry are affected. Due to the associated severe morbidity and unsatisfactory treatment options available, research on IBD pathogenesis is currently intense. It becomes apparent that a dysbalance of the entire intestinal flora leads to an activation of the immune system that can cause the disease.

MODE OF ACTION

GCX and GBX fortify the microbiome and help restoring its protective activity, thus GCX and GBX aim to restore the epithelial barrier and exert immunoregulatory function.

×

PRODUCT CANDIDATE OVERVIEW

GCX and GBX are product candidates intended to be orally administered to modulate the microbiome, activate metabolites and exert selective antimicrobial as well as immunomodulatory effects in humans. GCX and GBX contains a mix of tens of MO biosimilars in the form of glycopeptides.

PROGRESS

GCX and GBX are being tested in collaboration with University of Zürich (Switzerland) in mice models to demonstrate that they can control tumor growth alone or in enhancing the efficacy of immune-checkpoint inhibitors (ICIs).

UNMET NEED

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide while melanoma remains one of the most aggressive tumor types, with propensity to resist therapy. Despite immune checkpoint inhibitors (ICI) have revolutionized the treatment of some cancers, response rates remain low and differ between patients. Non-responding patients have very few alternative treatments, impacting survival rate. The microbiota has shown promises in controlling tumor growth and in modulating anti-tumor immunity and thus efficacy of ICI therapy. Solutions for prolonging quality and fulfilling lives resides in our ability to leverage the microbiome to help to provide sustainable, long-term control of the disease.

MODE OF ACTION

A high microbiome diversity is now recognized as an essential asset in immunotherapy treatment response. GCX and GBX fortify the microbiome and selectively grow specific bacterial commensals found to be more abundant in the gut of patients responding to immunotherapies, thus GCX and GBX aim to safely alter the microbiome to control tumor growth and improve treatment response.

Scientific publications & References

Our product candidates are supported by scientific publications involving members of the Gnubiotics team and by third-party evidence.

For more information

Fill in the form and our team will get back to you.